Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Adolescents (12 –17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on m...
Source: Allergy, Asthma and Clinical Immunology - Category: Allergy & Immunology Authors: Steven W. Yancey, Hector G. Ortega, Oliver N. Keene and Eric S. Bradford Tags: Letter to the editor Source Type: research